This is a protocol preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Method Article
Eiji Kobayashi
Keio University School of Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8617-3778
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Majority of research on human regenerative medicine has focused on the use of human mature cells/tissues and stem cell derived products. To ensure their safety and efficacy for clinical application, preclinical testing in large animals such as pigs, using pre-clinical and clinical matching protocols, is required. However, presently, there is no universal, stable, adjustable immunosuppressed pig model in which human regenerative cell and tissue products may be evaluated. Consequently, we established a controllable immunocompromised pig model by surgical excision of immune organs and varying the administration of immunosuppressive agents based on the physical condition and pharmacokinetic profile. Here, we describe the precise experimental procedure and provide information on immunosuppression therapies in different breeds of laboratory pigs. We provide practical information for the production of operational SCID pigs. We believe that our procedure may be immediately implemented in human-to-pig experiments, resulting in cost-benefit perspectives and furthering the development of new regenerative medicine.
Keywords
Translational research, immunosuppression, pig, transplantation
Figure 1
Figure 2
Figure 3
Figure 4
One of the authors declares competing financial interests: E.K. received the consultant fee from Takeda Pharmaceutical Company Ltd from Dec. 1st 2016 to Mar. 31st 2018, which was a parent company of Axcelead Drug Discovery Partners, Inc.
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Version History
CURRENT STATUS: Posted
Version 1
Posted 03 Oct, 2019
No community comments so far
Metrics
Comments: 0
HTML Views: ...
Associated Publications
Development of an immunodeficient pig model allowing long-term accommodation of artificial human vascular tubes
by Manabu Itoh, Yosuke Mukae, Takahiro Kitsuka, +13
Nature Communications (21 May, 2019)
Method Article
Eiji Kobayashi
Keio University School of Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8617-3778
Version History
CURRENT STATUS: Posted
Version 1
Posted 03 Oct, 2019
No community comments so far
Metrics
Comments: 0
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Majority of research on human regenerative medicine has focused on the use of human mature cells/tissues and stem cell derived products. To ensure their safety and efficacy for clinical application, preclinical testing in large animals such as pigs, using pre-clinical and clinical matching protocols, is required. However, presently, there is no universal, stable, adjustable immunosuppressed pig model in which human regenerative cell and tissue products may be evaluated. Consequently, we established a controllable immunocompromised pig model by surgical excision of immune organs and varying the administration of immunosuppressive agents based on the physical condition and pharmacokinetic profile. Here, we describe the precise experimental procedure and provide information on immunosuppression therapies in different breeds of laboratory pigs. We provide practical information for the production of operational SCID pigs. We believe that our procedure may be immediately implemented in human-to-pig experiments, resulting in cost-benefit perspectives and furthering the development of new regenerative medicine.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...
Associated Publications
Development of an immunodeficient pig model allowing long-term accommodation of artificial human vascular tubes
by Manabu Itoh, Yosuke Mukae, Takahiro Kitsuka, +13
Nature Communications (21 May, 2019)